Latest News for: pten

Edit

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

PR Newswire 14 Jul 2026
The FDA approval of capivasertib, in combination with abiraterone and prednisone, for adults with PTEN-deficient mAPMN/S prostate cancer marks a critical turning point for this disease, enabling a more personalized approach to treatment.
Edit

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing (Caris Life Sciences Inc)

Public Technologies 14 Jul 2026
The FDA approval of capivasertib, in combination with abiraterone and prednisone, for adults with PTEN-deficient mAPMN/S prostate cancer marks a critical turning point for this disease, enabling a more personalized approach to treatment.
Edit

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

The Milton Standard Journal 09 Jul 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--Jul 9, 2026-- ....
Edit

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer (NeoGenomics Inc)

Public Technologies 09 Jul 2026
) NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer ... Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP®.
Edit

Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (Form 6-K) (AstraZeneca plc)

Public Technologies 15 Jun 2026
Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer ... Capivasertib plus abiraterone in PTEN-deficient metastatic hormone sensitive prostate cancer.
Edit

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient ...

Rutland Herald 13 Jun 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Jun 12, 2026-- ....
Edit

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (AstraZeneca Pharmaceuticals LP)

Public Technologies 13 Jun 2026
Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease ... Today's approval makes clear the importance of testing for actionable biomarkers, including PTEN deficiency, in prostate cancer.".
Edit

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people ...

Nasdaq Globe Newswire 12 Jun 2026
RHHBY) announced today that the VENTANAⓇ PTEN (SP218) RxDx Assay is the first ...
Edit

Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (AstraZeneca plc)

Public Technologies 12 Jun 2026
) Based on results of CAPItello-281 which prospectively defined PTEN-deficient disease and showed Truqap combination reduced risk of radiographic disease progression or death by 19% ... Clinical implications of PTEN loss in prostate cancer.
Edit

TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

The Galveston Daily News 01 May 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Apr 30, 2026-- ....
Edit

Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer (Form 6-K) (AstraZeneca plc)

Public Technologies 01 May 2026
Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer ... Capivasertib plus abiraterone in PTEN-deficient metastatic hormone sensitive prostate cancer.
Edit

Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer (AstraZeneca plc)

Public Technologies 01 May 2026
"Patients identified to have PTEN-deficient metastatic hormone-sensitive prostate cancer have an aggressive form of the disease and currently experience poor outcomes ... PTEN-deficient tumours.9.
Edit

TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer (AstraZeneca Pharmaceuticals LP)

Public Technologies 01 May 2026
"Patients identified to have PTEN-deficient metastatic hormone-sensitive prostate cancer have an aggressive form of the disease and currently experience poor outcomes ... PTEN-deficient tumors.9.
Edit

Patterson-UTI (NASDAQ:PTEN) Beats Q1 CY2026 Sales Expectations

The Call 23 Apr 2026
PTEN) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, but sales fell by 12.7% year on year to $1.12 billion ... Patterson-UTI (PTEN) Q1 CY2026 Highlights. ... PTEN) provides contract ...
Edit

What To Expect From Patterson-UTI’s (PTEN) Q1 Earnings

The Call 21 Apr 2026
Oilfield services company Patterson-UTI (NASDAQ. PTEN) will be reporting earnings this Wednesday after market hours. Here’s what investors should know ... Patterson-UTI has missed Wall Street’s revenue estimates multiple times over the last two years ... .

Article Search

tools
×
×
×
×